GlaxoSmithKline Pakistan Ltd (GLAX)

Currency in PKR
385.75
+0.62(+0.16%)
Delayed Data·
GLAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
385.00387.52
52 wk Range
301.00481.00
Key Statistics
Bid/Ask
385.75 / 386.00
Prev. Close
385.13
Open
387.52
Day's Range
385-387.52
52 wk Range
301-481
Volume
223.65K
Average Volume (3m)
172.68K
1-Year Change
-6.07%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GLAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
580.00
Upside
+50.36%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low earnings multiple
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

GlaxoSmithKline Pakistan Company Profile

GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan. It deals in anti-infective, dermatology, respiratory, immunology, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakistan. GlaxoSmithKline Pakistan Limited is a subsidiary of GSK plc.

Employees
1700
Market
Pakistan

Compare GLAX to Peers and Sector

Metrics to compare
GLAX
Peers
Sector
Relationship
P/E Ratio
13.3x18.8x−0.6x
PEG Ratio
0.130.470.00
Price/Book
4.1x3.7x2.6x
Price / LTM Sales
2.0x2.0x3.2x
Upside (Analyst Target)
50.6%12.6%41.8%
Fair Value Upside
Unlock18.6%5.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 580.00
(+50.36% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 28.85%
Dividend Yield
3.89%
Industry Median 2.12%
Annualised payout
15.00
Paid annually
5-Years Growth
+20.11%
Growth Streak

Earnings

Latest Release
Oct 27, 2025
EPS / Forecast
6.40 / --
Revenue / Forecast
14.19B / --
EPS Revisions
Last 90 days

People Also Watch

13.33
AISH
+1.06%
86.20
CITI
+0.43%
529.93
BEST
+0.25%
10.65
GGGL
+1.04%

FAQ

What Is the GlaxoSmithKline Pakistan (GLAX) Share Price Today?

The live GlaxoSmithKline Pakistan share price today is 385.75

What Stock Exchange Does GlaxoSmithKline Pakistan (GLAX) Trade On?

GlaxoSmithKline Pakistan is listed and trades on the Karachi Stock Exchange.

What Is the Ticker (Stock Symbol) for GlaxoSmithKline Pakistan?

The stock symbol (also called a 'ticker') for GlaxoSmithKline Pakistan is "GLAX."

Does GlaxoSmithKline Pakistan Pay Dividends? What’s The Current GLAX Dividend Yield?

Yes, GLAX Pays Dividends to its Shareholders. The current GlaxoSmithKline Pakistan dividend yield is 3.89%.

What Is the Current GlaxoSmithKline Pakistan Market Cap?

As of today, GlaxoSmithKline Pakistan market capitalisation is 122.94B.

What Is GlaxoSmithKline Pakistan's (GLAX) Earnings Per Share (TTM)?

The GlaxoSmithKline Pakistan EPS is currently 28.85 (Trailing Twelve Months).

When Is the Next GlaxoSmithKline Pakistan Earnings Date?

GlaxoSmithKline Pakistan's next earnings report will be released on 25 Feb 2026.

Is GLAX a Buy or Sell From a Technical Analyst Perspective?

Based on today's GlaxoSmithKline Pakistan moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has GlaxoSmithKline Pakistan Stock Split?

GlaxoSmithKline Pakistan has split 9 times. (See the GLAX stock split history page for full effective split date and price information.)

How Many Employees Does GlaxoSmithKline Pakistan Have?

GlaxoSmithKline Pakistan has 1700 employees.

What is the current trading status of GlaxoSmithKline Pakistan (GLAX)?

As of 24 Dec 2025, GlaxoSmithKline Pakistan (GLAX) is trading at a price of 385.75, with a previous close of 385.13. The stock has fluctuated within a day range of 385.00 to 387.52, while its 52-week range spans from 301.00 to 481.00.

What Is GlaxoSmithKline Pakistan (GLAX) Price Target According to Analysts?

The average 12-month price target for GlaxoSmithKline Pakistan is PKR580, with a high estimate of PKR610 and a low estimate of PKR550. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +50.36% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.